OTCMKTS:HBPCF Helix Biopharma Q1 2025 Earnings Report $1.71 0.00 (0.00%) As of 09/18/2026 ProfileEarnings History Helix Biopharma EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHelix Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHelix Biopharma Announcement DetailsQuarterQ1 2025Date12/16/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsHelix Biopharma's next earnings date is estimated for Thursday, October 29, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Helix Biopharma Earnings HeadlinesHelix BioPharma Files Interim Financial Statements for April 2025June 16, 2025 | tipranks.comHelix BioPharma Appoints New CFO to Drive Strategic GrowthJune 2, 2025 | tipranks.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.September 20 at 1:00 AM | Paradigm Press (Ad)Helix BioPharma Secures $13 Million Financing to Advance Cancer TherapiesMay 14, 2025 | tipranks.comHelix BioPharma Appoints New CEO to Propel Clinical AdvancementsApril 10, 2025 | tipranks.comHelix BioPharma Engages ITG for Market-Making ServicesApril 3, 2025 | tipranks.comSee More Helix Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Helix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix Biopharma and other key companies, straight to your email. Email Address About Helix BiopharmaHelix Biopharma (OTCMKTS:HBPCF) is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents. The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth. Helix has investigated L-DOS47 in cancers including pancreatic cancer and non-small cell lung cancer. Helix BioPharma is headquartered in Canada and has conducted its drug-development activities through international clinical and research programs. As a clinical-stage biotechnology company, its products have primarily remained in development rather than being marketed as commercially available medicines.View Helix Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
